Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDURA XL vs PRECOSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.
Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.
Benign prostatic hyperplasia (FDA-approved),Hypertension (FDA-approved)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in patients with impaired glucose tolerance
4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.
Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.
15-22 hours in adults; terminal half-life is approximately 22 hours for extended-release formulation, allowing once-daily dosing. Half-life is prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life is approximately 2 hours for the parent drug, but clinical effect persists due to prolonged binding to intestinal alpha-glucosidases.
Extensively metabolized in the liver via CYP3A4 and CYP2D6; undergoes O-demethylation and hydroxylation.
Not extensively metabolized; primarily excreted unchanged in the urine as active drug. Small fraction undergoes intestinal metabolism by digestive enzymes.
Primarily hepatic metabolism via CYP3A4, with ~63% of the dose excreted in feces as metabolites and ~9% in urine as unchanged drug. Renal elimination of active drug is minimal (<1%).
Primarily excreted in feces (about 85%) as unchanged drug and metabolites, with less than 2% excreted renally as active metabolites.
~98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Low protein binding, approximately 5%, primarily to albumin.
1.9-3.1 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle.
Volume of distribution is approximately 0.3 L/kg, indicating minimal distribution into tissues and predominantly confined to extracellular fluid.
Oral extended-release: ~85% relative to immediate-release formulation, with minimal first-pass metabolism. Food does not significantly affect absorption.
Oral bioavailability is low, approximately 2%, due to local action in the gastrointestinal tract and minimal systemic absorption.
No dose adjustment required for renal impairment (GFR ≥30 m L/min). For GFR <30 m L/min, use with caution; no specific dose recommendation available.
No dose adjustment recommended for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <25 m L/min/1.73 m²).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), start at 2 mg once daily and titrate cautiously.
No dose adjustment recommended for mild hepatic impairment. Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); avoid use.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Not recommended for pediatric patients (safety and efficacy not established).
Initiate at 2 mg once daily with breakfast; titrate slowly to avoid orthostatic hypotension. Monitor blood pressure closely.
No specific dose adjustment required; monitor renal function due to age-related decline. Start at low end of dosing range (25 mg three times daily).
None.
None.
Orthostatic hypotension and syncope, especially with first dose or dose increase,Priapism (rare),Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery,Hepatic impairment: dose adjustment may be needed
Hypoglycemia: Acarbose does not cause hypoglycemia when used alone, but may increase risk when combined with sulfonylureas or insulin. Hypoglycemic episodes should be treated with glucose (dextrose), not sucrose.,Hepatic injury: Rare cases of acute hepatitis, jaundice, and fulminant hepatic failure; monitor liver function tests.,Renal impairment: Contraindicated in patients with Cr Cl <25 m L/min.,Gastrointestinal effects: Frequently causes flatulence, diarrhea, and abdominal discomfort due to undigested carbohydrates; these effects may diminish with continued use.
Hypersensitivity to doxazosin or any component,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Hypersensitivity to acarbose or any component,Diabetic ketoacidosis,Cirrhosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction or predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Conditions that may deteriorate as a result of increased intestinal gas formation (e.g., Roemheld syndrome),Severe renal impairment (Cr Cl <25 m L/min)
Avoid grapefruit and grapefruit juice as they may increase doxazosin concentrations. No other significant food interactions known. Alcohol may exacerbate hypotensive effects.
Avoid sucrose and table sugar as they may worsen GI side effects. Dietary carbohydrates increase efficacy but also GI side effects. Precose alone does not cause hypoglycemia; however, if used with insulin or sulfonylureas, hypoglycemia must be treated with glucose (dextrose) because absorption of complex sugars and sucrose is inhibited.
Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third trimesters: Potential for reduced placental perfusion due to alpha-blockade; avoid use unless benefit outweighs risk.
Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.
Unknown if excreted in human milk; M/P ratio not available. Caution advised; use only if clearly needed.
Unknown if excreted in human milk. Caution advised. M/P ratio not established.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume. Use lowest effective dose and monitor clinical response.
No dose adjustment recommended; monitor glucose control closely as pharmacokinetics may change; insulin often preferred.
CARDURA XL (doxazosin extended-release) is an alpha-1 adrenergic blocker primarily used for benign prostatic hyperplasia (BPH). Its prolonged action reduces the risk of first-dose syncope compared to immediate-release. Do not crush or chew; swallow whole. Monitor blood pressure in patients also on antihypertensives due to additive hypotensive effects. Avoid use in patients with history of orthostatic hypotension or micturition syncope.
Precose (acarbose) is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is most effective for postprandial hyperglycemia. Must be taken with the first bite of each main meal. Avoid use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Can cause elevated liver enzymes; monitor LFTs every 3 months during first year. Hypoglycemia from other agents should be treated with glucose (not sucrose) because sucrase is inhibited.
Take exactly as prescribed, once daily with or without food. Swallow tablet whole, do not crush or chew.,Avoid grapefruit juice as it may alter drug levels.,Possible side effects include dizziness, fatigue, and nasal congestion. Rise slowly from sitting or lying to reduce fall risk.,May cause orthostatic hypotension especially after first dose or dose increase.,If you experience lightheadedness or fainting, contact your doctor.
Take this medication with the first bite of each main meal.,If you experience low blood sugar, treat it with glucose tablets or milk, not fruit juice or regular soda.,Common side effects include flatulence, diarrhea, and abdominal pain, which often decrease with time.,Do not take this drug if you have severe kidney problems or certain bowel diseases.,Report any signs of liver problems (yellow skin/eyes, dark urine, abdominal pain) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDURA XL vs PRECOSE, answered by our medical review team.
CARDURA XL is a Alpha-1 Blocker Antihypertensive that works by Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.. PRECOSE is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDURA XL and PRECOSE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDURA XL is: 4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.. The standard adult dose of PRECOSE is: Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDURA XL and PRECOSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDURA XL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third tr. PRECOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.